| abstract |
The present invention relates to compounds of general formula I wherein R 1 is -OR 1 ', heterocycloalkyl, aryl or heteroaryl, which is unsubstituted or substituted by lower alkyl or halogen; R 1 'is lower alkyl, lower alkyl substituted by halogen or is - (CH 2) o -cycloalkyl; R 2 is -S (O) 2-lower alkyl, -S (O) 2 NH-lower alkyl, NO 2 or CN; R 3 is aryl or heteroaryl, which is unsubstituted or substituted with one to three substituents, selected from the group consisting of lower alkyl, lower alkoxy, CN, NO 2, halogen, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, aryl or sulfonamide ; X is a bond, -CH2 -, -NH-, -CH2O- or -OCH2-; n is 1 or 2; m is 1 or 2; o is 0 or 1; pharmaceutically acceptable acid addition salts thereof, pharmaceutical compositions containing them and their use in the treatment of neurological and neuropsychiatric disorders. It has been found that the compounds of general formula I are good inhibitors of glycine transporter 1 (GlyT-1). |